Three-quarters of the people who got Finch Therapeutics’ microbe-based pill for potentially deadly C. difficile infections appeared to be cured, an improvement over rates for the current standard treatment, the company announced Friday.
Finch’s announcement makes it the second microbiome company to announce positive results for a microbe-based drug this year. But it is the first to do so with an oral treatment; Rebiotix, announced that its Phase 3 trial for an enema-based therapy succeeded in early May.
“This will be an important proof point for the field,” said Finch CEO Mark Smith. “There’s a lot of people that have been excited about the promise of the microbiome and who have believed that it’s gonna be an important modality. And I think the question for a lot of people has been when and how.”
About the Author Reprints
